Post-Operative Nausea and Vomiting Market Report 2025

The post-operative nausea and vomiting market size has grown strongly in recent years. It will grow from $2.11 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth during the historic period can be attributed to increased research and development activities, a rising demand for advanced therapies, higher healthcare expenditures, a growing focus on personalized medicine, and the expanding adoption of digital health technologies.

The post-operative nausea and vomiting market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The projected growth during the forecast period can be attributed to the increasing demand for pharmaceuticals, the rise of combination therapy, growing awareness and healthcare investments, a rising geriatric population, and the increasing number of cancer cases. Key trends expected during this period include advancements in antiemetic therapies, strategic collaborations, innovative drug formulations, the integration of advanced diagnostic tools, and the development of electronic simulation devices.

The increasing number of surgical procedures is expected to drive the growth of the post-operative nausea and vomiting market. Surgical procedures involve medical interventions that utilize tools to diagnose, treat, or remove damaged tissues, organs, or abnormalities through cutting or manipulation. The rise in surgical procedures is attributed to advancements in medical technology, which have made surgeries safer, more effective, and minimally invasive, leading to greater patient acceptance and broader applicability. Effective management of post-operative nausea and vomiting enhances surgical procedures by improving patient comfort, reducing recovery time, minimizing complications, and ensuring smoother post-operative care, ultimately leading to better surgical outcomes. For example, in November 2024, the Australian Institute of Health and Welfare reported that during the 2023-24 period, 771,600 patients were admitted for surgery from public hospital elective surgery waiting lists, reflecting a 4.9% increase compared to 2022-23. This trend highlights the growing number of surgical procedures, which is fueling the expansion of the post-operative nausea and vomiting market.

Companies in the post-operative nausea and vomiting market are focusing on developing critical injectable medications using advanced emulsion formulations and sustained-release technology to improve treatment efficacy and provide prolonged symptom relief for surgical patients. These critical injectable medications are essential drugs administered via injection to deliver immediate and effective treatment for serious or urgent medical conditions. For example, in July 2024, Avenacy, a US-based specialty pharmaceutical company, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials. This formulation helps healthcare providers reduce dosing errors and improve patient safety. The injection is designed to prevent nausea and vomiting induced by chemotherapy and to manage post-operative nausea and vomiting for up to 24 hours following surgery, offering a reliable treatment option for patients at risk of these conditions.

In June 2022, Eagle Pharmaceuticals, Inc., a US-based pharmaceutical company, acquired Acacia Pharma Group plc for an undisclosed amount. This acquisition aims to strengthen Eagle Pharmaceuticals' acute care portfolio and enhance hospital sales capabilities by leveraging its network to promote BARHEMSYS for post-operative nausea and vomiting rescue treatment and BYFAVO for procedural sedation. The deal addresses significant unmet clinical needs and aims to improve patient care. Acacia Pharma Group plc, a UK-based hospital pharmaceutical company, specializes in supportive care treatments for post-operative nausea and vomiting.

Major players in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited., Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy's Laboratories, Kyowa Hakko Kirin Taiwan Co. Ltd., Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc., Camurus AB, Helsinn Healthcare SA, Heron Therapeutics Inc., Advacare Pharma.

North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in post-operative nausea and vomiting report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the post-operative nausea and vomiting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Post-operative nausea and vomiting (PONV) is a common complication that typically occurs within 24 to 48 hours after surgery, often triggered by anesthesia, pain medications, or the body’s response to surgical stress. This condition can significantly hinder a patient's recovery, leading to discomfort, delayed healing, and an increased risk of complications such as dehydration or electrolyte imbalances.

The main treatments for post-operative nausea and vomiting include serotonin antagonists, steroids, dopamine antagonists, neurokinin NK-1 receptor antagonists, non-pharmacological treatments, and others. Serotonin antagonists are medications that block serotonin receptors, preventing nausea and vomiting signals from reaching the brain. The various routes of administration include oral, intravenous, transdermal, and others, catering to different patient demographics such as pediatric, adult, and geriatric patients. Surgical procedures where PONV treatments are commonly used include orthopedic, gynecological, general, cardiac, and ophthalmic surgeries. These treatments are utilized by a range of end-users, including hospitals, ambulatory surgical centers, specialty clinics, and others.

The post-operative nausea and vomiting market research report is one of a series of new reports that provides post-operative nausea and vomiting market statistics, including post-operative nausea and vomiting industry global market size, regional shares, competitors with a post-operative nausea and vomiting market share, detailed post-operative nausea and vomiting market segments, market trends and opportunities, and any further data you may need to thrive in the post-operative nausea and vomiting industry. This post-operative nausea and vomiting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The post-operative nausea and vomiting market consists of revenues earned by entities by providing services such as patient monitoring, anesthesia management, antiemetic drug administration, postoperative care, and clinical counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The post-operative nausea and vomiting market also includes sales of antiemetic drugs, intravenous fluids, nausea relief patches, oxygen therapy devices, and acupuncture kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.